SynOx Therapeutics, a late-stage clinical biopharmaceutical company, has concluded a $75 million Series B financing, co-led by Forbion, HealthCap, and Bioqube Ventures. The funding aims to propel the registrational Phase 3 clinical and CMC data generation for emactuzumab, a potentially groundbreaking CSF-1(R) inhibiting monoclonal antibody targeting Tenosynovial Giant Cell Tumour (TGCT), a debilitating condition affecting major joints like the knee and hip. TGCT significantly impacts patients' quality of life, often requiring surgical intervention with high recurrence rates. Emactuzumab has exhibited promising clinical activity, with a 71% objective response rate in earlier trials, prompting the initiation of a Phase 3 trial (TANGENT) to further evaluate its efficacy and safety in TGCT patients. Moreover, the addition of experienced professionals like Dr. Carlo Incerti and Jon Edwards to the Board of Directors underscores SynOx's commitment to advancing emactuzumab and addressing unmet medical needs, signaling a transformative phase for the company.
SynOx Therapeutics Secures $75m For Phase 3 TGCT Treatment Trial
1 min read
23 April
In case you have found a mistake in the text, please send a message to the author by selecting the mistake and pressing Ctrl-Enter.
No comments yet